D-二聚体在子宫癌、宫颈癌和卵巢癌患者血中表达
|
摘要
目的探讨子宫颈癌、子宫癌和卵巢癌患者血D-二聚体的差异及临床意义。方法收集子宫颈癌36例,子宫癌31例,卵巢癌30例;子宫颈炎患者30例,子宫肌瘤患者32例,卵巢囊肿28例,健康体检者35例,测定研究对象血D-二聚体。结果子宫颈癌患者血D-二聚体含量高于子宫颈炎患者;子宫癌患者血D-二聚体含量高于子宫肌瘤患者;卵巢癌患者血D-二聚体含量高于卵巢囊肿患者。子宫颈癌、子宫癌、卵巢癌患者血D-二聚体含量高于健康对照组(P <0.05)。三种癌症患者随着分期的升高,其血D-二聚体含量逐渐升高,差异有统计学意义(P <0.05)。ROC曲线显示,血D-二聚体含量对子宫颈癌、子宫癌、卵巢癌有较高的诊断价值。结论检测血D-二聚体含量对子宫颈癌、子宫癌和卵巢癌诊断有着较高的诊断价值。
Objective To investigate the difference of D-Dimer in cervical cancer, uterine cancer and ovarian cancer and its clinical significance. Methods 36 cases of cervical cancer, 31 cases of uterine cancer, 30 cases of ovarian cancer, 30 cases of cervicitis, 32 cases of uterine fibroids, 28 cases of ovarian cysts, 35 cases of healthy people were enrolled in the study, and the blood D-Dimer of the subjects was determined. Results The level of D-Dimer in patients with cervical cancer was higher than that in patients with cervicitis, the level of D-Dimer in patients with uterine cancer was higher than that in patients with uterine fibroids, and the level of D-Dimer in patients with ovarian cancer was higher than that in patients with ovarian cysts. The levels of D-Dimer in patients with cervical cancer, uterine cancer and ovarian cancer were significantly higher than those in healthy control group(P < 0.05). The levels of D-Dimer in blood of three kinds of cancer patients increased with the increase of stage(P < 0.05). ROC curve showed that D-Dimer content in blood was of higher diagnostic value for cervical cancer, uterine cancer and ovarian cancer. Conclusion Detection of D-Dimercontent in blood has high diagnostic value for cervical cancer, uterine cancer and ovarian cancer.
Objective To investigate the difference of D-Dimer in cervical cancer, uterine cancer and ovarian cancer and its clinical significance. Methods 36 cases of cervical cancer, 31 cases of uterine cancer, 30 cases of ovarian cancer, 30 cases of cervicitis, 32 cases of uterine fibroids, 28 cases of ovarian cysts, 35 cases of healthy people were enrolled in the study, and the blood D-Dimer of the subjects was determined. Results The level of D-Dimer in patients with cervical cancer was higher than that in patients with cervicitis, the level of D-Dimer in patients with uterine cancer was higher than that in patients with uterine fibroids, and the level of D-Dimer in patients with ovarian cancer was higher than that in patients with ovarian cysts. The levels of D-Dimer in patients with cervical cancer, uterine cancer and ovarian cancer were significantly higher than those in healthy control group(P < 0.05). The levels of D-Dimer in blood of three kinds of cancer patients increased with the increase of stage(P < 0.05). ROC curve showed that D-Dimer content in blood was of higher diagnostic value for cervical cancer, uterine cancer and ovarian cancer. Conclusion Detection of D-Dimercontent in blood has high diagnostic value for cervical cancer, uterine cancer and ovarian cancer.
引文
[1]高翠红,高庆双,彭利红.卵巢癌患者外周血D-二聚体、FIB水平与IL-6动态变化的研究[J].中国免疫学杂志,2015,31(4):534-536.
[2]张玉虹,刘阳晨. D-二聚体与消化道恶性肿瘤[J].现代肿瘤医学,2015,23(12):1747-1750.
[3]贺家勇,王国良,张华彬,等.恶性肿瘤患者凝血功能相关指标与其临床特征关系的研究[J].国际检验医学杂志,2015,36(17):2485-2486,2489.
[4]程雪菊,徐凤娟,马凯来.卵巢癌患者血浆D-二聚体水平变化及意义[J].山东医药,2013,53(40):41-42.
[5]刘列.卵巢癌患者血浆D-二聚体水平变化及意义[J].中国社区医师,2014,30(26):107,109.
[6]吴雪峰,李晓鸥,张晓伟.卵巢癌患者血浆D-二聚体水平与静脉血栓栓塞的关系研究[J].中国实验诊断学,2016,20(10):1718-1720.
[7]时慧.卵巢癌患者D-二聚体、CA125及CA199联合检测的临床意义[J].实验与检验医学,2016,34(6):783-785,795.
[8]兰新志,赵丹丹.血浆D-二聚体、Fbg及CA125水平变化在卵巢癌中的临床意义[J].国际检验医学杂志,2016,37(23):3343-3345.
[9]原娜,王磊,武雪亮.凝血酶原片段1+2、血浆D-二聚体预测恶性肿瘤PICC相关性静脉血栓的研究[J].山西医科大学学报,2017,48(7):694-697.
[10]卢建新,陈晓敏,陈作波.晚期肝癌患者血浆纤维蛋白原和D-二聚体水平变化的影响[J].实用癌症杂志,2018,33(6):1011-1013.
[11]刘建军,崔林,刘兴祥,等.血浆D-二聚体水平与卵巢癌患者临床特征及化疗预后的关系研究[J].癌症进展,2018,16(6):766-769.
[12]钟春生,郑岚,郑浩. D-二聚体、纤维蛋白原和β2-微球蛋白在恶性肿瘤诊断中的应用[J].淮海医药,2014,32(1):99-100.
[2]张玉虹,刘阳晨. D-二聚体与消化道恶性肿瘤[J].现代肿瘤医学,2015,23(12):1747-1750.
[3]贺家勇,王国良,张华彬,等.恶性肿瘤患者凝血功能相关指标与其临床特征关系的研究[J].国际检验医学杂志,2015,36(17):2485-2486,2489.
[4]程雪菊,徐凤娟,马凯来.卵巢癌患者血浆D-二聚体水平变化及意义[J].山东医药,2013,53(40):41-42.
[5]刘列.卵巢癌患者血浆D-二聚体水平变化及意义[J].中国社区医师,2014,30(26):107,109.
[6]吴雪峰,李晓鸥,张晓伟.卵巢癌患者血浆D-二聚体水平与静脉血栓栓塞的关系研究[J].中国实验诊断学,2016,20(10):1718-1720.
[7]时慧.卵巢癌患者D-二聚体、CA125及CA199联合检测的临床意义[J].实验与检验医学,2016,34(6):783-785,795.
[8]兰新志,赵丹丹.血浆D-二聚体、Fbg及CA125水平变化在卵巢癌中的临床意义[J].国际检验医学杂志,2016,37(23):3343-3345.
[9]原娜,王磊,武雪亮.凝血酶原片段1+2、血浆D-二聚体预测恶性肿瘤PICC相关性静脉血栓的研究[J].山西医科大学学报,2017,48(7):694-697.
[10]卢建新,陈晓敏,陈作波.晚期肝癌患者血浆纤维蛋白原和D-二聚体水平变化的影响[J].实用癌症杂志,2018,33(6):1011-1013.
[11]刘建军,崔林,刘兴祥,等.血浆D-二聚体水平与卵巢癌患者临床特征及化疗预后的关系研究[J].癌症进展,2018,16(6):766-769.
[12]钟春生,郑岚,郑浩. D-二聚体、纤维蛋白原和β2-微球蛋白在恶性肿瘤诊断中的应用[J].淮海医药,2014,32(1):99-100.